[1]翟恒博,综述,刘俊,等.缺血性心脏病再认识[J].心血管病学进展,2016,(4):395-400.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.018]
 ZHAI Hengbo,LIU Jun.Rethinking of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(4):395-400.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.018]
点击复制

缺血性心脏病再认识()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年4期
页码:
395-400
栏目:
综述
出版日期:
2016-08-15

文章信息/Info

Title:
Rethinking of Ischemic Heart Disease
作者:
翟恒博综述刘俊审校
大连医科大学附属第一医院心血管内科,辽宁 大连 116000
Author(s):
ZHAI HengboLIU Jun
1. Department of Cardiology,The First Affiliated Hospital of Dalian Medical University,Dalian 116000,Liaoning,China
关键词:
缺血性心脏病 心肌缺血 再认识 发病机制 诊断 治疗
Keywords:
Ischemic heart disease Myocardial ischemia Recognition Pathogenesis Diagnosis Therapy
分类号:
R541.4
DOI:
10.16806/j.cnki.issn.1004-3934.2016.04.018
文献标志码:
A
摘要:
缺血性心脏病是一种常见的导致心肌缺血、缺氧甚至坏死的慢性非传染性疾病,严重地威胁着人群健康。既往认为,缺血性心脏病的发生主要与冠状动脉的功能或器质性改变所引起的冠状动脉血流和心肌需氧量之间的不平衡有关。近年来,随着各国学者对缺血性心脏病研究的不断深入,对该病的认识逐渐从“以冠状动脉狭窄为中心”到“心肌缺血为中心”转变,即缺血性心脏病的发生是冠状动脉狭窄、炎症反应、血小板和凝血功能亢进、血管痉挛、微血管功能异常和内皮功能障碍等多个因素共同作用的结果。现从发病机制、临床诊断和干预措施等多个方面就新近缺血性心脏病进展做一简要介绍。
Abstract:
Ischemic heart disease(IHD)is a common chronic non-communicable disease that leads to myocardial ischemia, hypoxia and even necrosis, posing a serious threat to human health. It is believed previously that the occurrence of IHD is mainly related to imbalance between coronary blood flow and myocardial oxygen demand caused by functional or organic changes in coronary artery. In recent years, IHD research in various countries has been increased, and their awareness of the disease is gradually changed from “the center of coronary artery stenosis” to “the center of myocardial ischemia”,meaning that the occurrence of IHD is the result of concurrent multiple factors such as coronary artery stenosis, inflammatory response, platelets and coagulation hyperthyroidism, vasospasm, microvascular dysfunction and endothelial dysfunction and more. This paper attempts to make a brief introduction of recent progress of IHD from many aspects of pathogenesis, clinical diagnosis and intervention measures.

参考文献/References:

[1] Barquera S, Pedroza-Tobías A,Medina C,et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease[J]. Arch Med Res,2015,46(5):328-338.
[2] Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010[J]. Lancet,2013,9882(9882):1987-2015.
[3] Mario M, Merz CNB, Boden WE, et al. Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link![J]. J Am Coll Cardiol,2012,60(11):951-956.
[4] Caruso MV,de Rosa S,Indolfi C,et al.Computational analysis of stenosis geometry effects on right coronary hemodynamics[J].Conf Proc IEEE Eng Med Biol Soc,2015,2015:981-984.
[5] Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators[J]. N Engl J Med,1999, 341(4):226-232.
[6] Sivabaskari P, Tracy A, Dreyer RP, et al. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries[J]. Circulation, 2015,131(10):861-870.
[7] Planer D,Mehran R,Ohman EM,et al. Prognosis of patients with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease:propensity-matched analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial[J].Circ Cardiovasc Interv,2014,7(3):285-293.
[8] Shah PK. Biomarkers of plaque instability[J].Curr Cardiol Rep,2014,16(12):1-8.
[9] Jacob Fog B, Fumiyuki O, Renu V, et al. Mechanisms of plaque formation and rupture[J]. Circ Res,2014,114(12):1852-1866.
[10] Kalaichelvan U, Vijayakumar S, Balaji P, et al. Primary percutaneous thrombus aspiration alone as definitive intervention for left main coronary artery occlusion presenting as acute anterior wall ST elevation myocardial infarction[J]. Heart Lung Circ,2014,23(2):166-170.
[11] Shibata T, Kawakami S, Noguchi T, et al. Prevalence, clinical features, and prognosis of acute myocardial infarction attributable to coronary artery embolism[J]. Circulation,2015,132(4):241-250.
[12] Sueda S, Miyoshi T, Sasaki Y, et al. One of six patients with non-ischemic heart disease exhibit provoked coronary spasms:non-ischemic heart disease associated with ischemia?[J]. Intern Med,2015,54(3):281-286.
[13] Melody Z, Mehta PK, Merz CNB.Provocative testing for coronary reactivity and spasm[J]. J Am Coll Cardiol,2013,63(2):103-109.
[14] Ong P,Athanasiadis A,Borgulya G,et al.Clinical usefulness,angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries[J].Circulation,2014,129(17):1723-1730.
[15] Morikawa Y, Mizuno Y, Harada E, et al. Aerobic interval exercise training in the afternoon reduces attacks of coronary spastic angina in conjunction with improvement in endothelial function, oxidative stress, and inflammation[J]. Coron Artery Dis,2013,24(3):177-182.
[16] Tsujita K, Sakamoto K, Kojima S,et al. Coronary plaque component in patients with vasospastic angina:a virtual histology intravascular ultrasound study[J]. Int J Cardiol,2013, 168(3):2411-2415.
[17] Likoff W, Segal BL, Kasparian H. Paradox of normal selective coronary arteriograms in patients considered to have unmistakable coronary heart disease[J]. N Engl J Med,1967, 276(19):1063-1066.
[18] Kemp HG. Left ventricular function in patients with the anginal syndrome and normal coronary arteriograms[J]. Am J Cardiol,1973,32(3):375-376.
[19] Cannon RO 3rd,Epstein SE.“Microvascular angina”as a cause of chest pain with angiographically normal coronary arteries[J]. Am J Cardiol,1988, 61(15):1338-1343.
[20] Petersen JW, Pepine CJ. Microvascular coronary dysfunction and ischemic heart disease: where are we in 2014?[J]. Trends Cardiovasc Med,2015,25(2):98-103.
[21] Murthy VL, Masanao N, Taqueti VR, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes[J]. Circulation,2014,129(24):2518-2527.
[22] Matsuzawa Y, Guddeti RR, Kwon TG, et al. Treating coronary disease and the impact of endothelial dysfunction[J]. Prog Cardiovasc Dis,2015,57(5):431-442.
[23] Matsuzawa Y, Sugiyama S, Sumida H, et al.Peripheral endothelial function and cardiovascular events in high-risk patients[J].J Am Heart Assoc,2013, 2(2):e000426-e000426.
[24] Douglas PS, Udo H, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease[J]. N Engl J Med,2015,372(1):89-91.
[25] Bernard DB, Fearon WF, Pijls NHJ, et al. Fractional flow reserve-guided PCI for stable coronary artery disease[J]. N Engl J Med,2014,371(13):1208-1217.
[26] Hanson ID, Goldstein JA, Dixon SR, et al. Comparison of coronary artery lesion length by NIRS-IVUS versus angiography alone[J]. Coron Artery Dis,2015,26(6):484-489.
[27] Sedlis SP, Hartigan PM, Teo KK, et al. Effect of PCI on long-term survival in patients with stable ischemic heart disease[J]. N Engl J Med,2015,373(20):1937-1946.
[28] Luo B, Wu P, Bu T, et al. All-cause mortality and cardiovascular events with nicorandil in patients with IHD:systematic review and meta-analysis of the literature[J]. Int J Cardiol,2014,176(3):661-669.
[29] Steg P, Lopez-De-Sà E, Schiele F, et al. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention:a randomized, placebo-controlled, double-blind, pilot study[J]. Eur Heart J Acute Cardiovasc Care,2013,2(3):270-279.
[30] Gutierrez JA, Karwatowska-Prokopczuk E, Murphy SA, et al. Effects of ranolazine in patients with chronic angina in patients with and without percutaneous coronary intervention for acute coronary syndrome: observations from the MERLIN-TIMI 36 trial[J]. Clin Cardiol,2015,38(8):469-475.
[31] Tagliamonte E, Rigo F, Cirillo T,et al. Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease[J]. Echocardiography,2015,32(3):516-521.
[32] Weiss S, Weintraub W. Revascularization vs. medical therapy in stable ischemic heart disease[J]. Prog Cardiovasc Dis,2015,58(3):299-305.
[33] Pepine CJ, Douglas PS, Pepine CJ, et al. Rethinking stable ischemic heart disease:is this the beginning of a new era?[J]. J Am Coll Cardiol,2012,60(11):957-959.

相似文献/References:

[1]宋林声,综述,陆地,等.低剂量多巴酚丁胺负荷磁共振成像在缺血性心脏病中的应用研究[J].心血管病学进展,2016,(3):285.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.018]
 SONG Linsheng,LU Di,ZHAO Xinxiang.Low-dose Dobutamine Stress MRI Myocardial Perfusion and Assessment of Myocardial Viability[J].Advances in Cardiovascular Diseases,2016,(4):285.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.018]
[2]施国荣 刘婷婷 田欣 祝自新 郑文荣 王宇峰 孙芳玲 王文.Eph/ephrin信号通路在缺血性心脏病中血管生成中的研究进展[J].心血管病学进展,2021,(2):158.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.016]
 Shi Guorong,Liu Tingting,Tian Xin,et al.Research Progress of Eph/ephrin Signaling Pathway in Angiogenesis of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2021,(4):158.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.016]
[3]肖轶 余国龙.不同干细胞来源的外泌体在缺血性心脏病中的促血管新生作用[J].心血管病学进展,2022,(4):293.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.002]
 XIAO Yi,YU Guolong?/html>.Application of Exosomes Derived from Various Stem Cells?n Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2022,(4):293.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.002]
[4]琚敏 汪蕾 宋雷 方纬.心脏交感神经显像的临床应用和研究进展[J].心血管病学进展,2023,(1):16.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.005]
 JU Min,WANG Lei,SONG Lei,et al.Clinical Application and Research Progress of Cardiac Sympathetic Imaging[J].Advances in Cardiovascular Diseases,2023,(4):16.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.005]
[5]庞自豪 贾青青 韩博文 张莉.药物调控哺乳动物雷帕霉素靶蛋白相关信号通路在缺血性心脏病中的研究进展[J].心血管病学进展,2024,(4):326.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.009]
 PANG Zihao,JIA Qingqing,HAN Bowen,et al.Research Progress In Drug Regulated mTOR Related Signaling Pathway?span>In Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2024,(4):326.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.009]

备注/Memo

备注/Memo:
作者简介:翟恒博(1990—),在职硕士,主要从事冠心病研究。Email:zhaihengbo1990@163.com 通信作者:刘俊(1961—),主任医师,主要从事冠心病心肌梗死、心绞痛、高血压病、心力衰竭及心肌病等心血管病的临床研究。Email:dalianliujun@medmail.com.cn
更新日期/Last Update: 2016-07-25